Gilead Provides Update on Phase 3 EVOKE-01 Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- Japan has no plans to overhaul pension funds' asset allocation, sources say
RBC Capital Out Negative on Gilead Sciences (GILD), 'see the stock as lacking'
January 22, 2024 9:27 AM ESTRBC Capital analyst Brian Abrahams reiterated a Sector Perform rating and $78.00 price target on Gilead Sciences (NASDAQ: GILD).
The analyst comments "This morning GILD reported that their EVOKE-01 trial of Trodelvy in 2L NSCLC did not meet its primary OS endpoint, though did show numerically favorable trends vs docataxel across both squamous and non-squamous histologies. Following AZN's dato data and our KOL feedback, as well as the recent ph.II results in 1L for Trodelvy, we had been cautious as to whether the potential longer duration of use of an ADC... More
AstraZeneca (AZN) Gains After Gilead Sciences (GILD) Study in Lung Cancer Fails
January 22, 2024 8:47 AM ESTAstraZeneca (NASDAQ: AZN) Gains After Gilead Sciences (NASDAQ: GILD) Study in Lung Cancer Fails
GILD -9%AZN +3% Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in... MoreGilead Sciences (GILD) Sinks 11% After Lung Cancer Study Fails
January 22, 2024 8:42 AM ESTGilead Sciences Sinks 11% After Lung Cancer Study Fails
A numerical improvement in OS favoring SG was observed in the study, including in patients with both squamous and non-squamous histology. The safety profile for Trodelvy was consistent with prior studies. Trodelvy was generally well tolerated, and no new safety signals... More